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Abstract
Background: There are two selenophosphate synthetases (SPSs) in higher eukaryotes, SPS1 and SPS2. Of these two
isotypes, only SPS2 catalyzes selenophosphate synthesis. Although SPS1 does not contain selenophosphate
synthesis activity, it was found to be essential for cell growth and embryogenesis in Drosophila. The function of
SPS1, however, has not been elucidated.
Results: Differentially expressed genes in Drosophila SL2 cells were identified using two-way analysis of variance
methods and clustered according to their temporal expression pattern. Gene ontology analysis was performed
against differentially expressed genes and gene ontology terms related to vitamin B6 biosynthesis were found to
be significantly affected at the early stage at which megamitochondria were not formed (day 3) after SPS1
knockdown. Interestingly, genes related to defense and amino acid metabolism were affected at a later stage (day
5) following knockdown. Levels of pyridoxal phosphate, an active form of vitamin B6, were decreased by SPS1
knockdown. Treatment of SL2 cells with an inhibitor of pyridoxal phosphate synthesis resulted in both a similar
pattern of expression as that found by SPS1 knockdown and the formation of megamitochondria, the major
phenotypic change observed by SPS1 knockdown.
Conclusions: These results indicate that SPS1 regulates vitamin B6 synthesis, which in turn impacts various cellular
systems such as amino acid metabolism, defense and other important metabolic activities.
Background
Selenium has been reported to provide many health
benefits in animals, including humans, when obtained
from the diet in adequate amounts. For example, sele-
nium has been known to play roles in cancer preven-
tion, aging retardation, immune augmentation,
prevention of heart diseases, muscle development and
development [[1-4] and references therein]. Many of the
health benefits of selenium are mediated by selenopro-
teins, which contain selenocysteine (Sec) as a selenium
containing amino acid [3].
Selenophosphate synthetase (SPS) synthesizes seleno-
phosphate (SeP), the active selenium donor in Sec
biosynthesis, using selenide and ATP as substrates [5].
SeP serves as a selenium donor during Sec biosynthesis
[6]. Sec is contained in all selenoproteins [7]. SPS was
first isolated from Escherichia coli as one of the enzymes
involved in selenoprotein synthesis and was designated
SelD [8]. Only one type of SPS, SelD, exists in lower
eukaryotes and eubacteria, however, there are two iso-
forms of SPS, SPS1 and SPS2, that occur in higher eukar-
yotes [9]. One of the major differences in the sequences
between SPS1 and SPS2 is that SPS1 has an arginine at
the position corresponding to Sec in SPS2 [10].
Although it is not clear why there are two SPSs in
higher eukaryotes, recent studies have shown that SPS2
synthesizes SeP from selenide and ATP in vitro, while
SPS1 does not have this activity [11]. Loss of function in
NIH3T3 cells using RNA interference technology
showed that SPS2 is required for selenoprotein bio-
synthesis, while SPS1 does not affect the biosynthesis of
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red beetle and silkworm have lost the selenoprotein
synthesizing machinery including SPS2, SPS1 is still
encoded in the genome of these insects, suggesting SPS1
is required for a function other than SeP synthesis [13].
Although SPS1 does not catalyze SeP biosynthesis, it
plays essential roles in the cell. When the gene encoding
SPS1 (SPS1, also designated patufet) was deleted in Dro-
sophila, the embryo showed lethality during develop-
ment [14], and reactive oxygen species (ROS) levels
increased [15]. The haploinsufficiency of genes involved
in the Ras-regulated signaling pathway was also sup-
pressed by SPS1 knockout in Drosophila [16]. From the
finding that the SelD (E. coli SPS) mutant of E. coli can
be complemented by human SPS1 only when L-Sec is
supplemented in the medium, it was suggested that
SPS1 is involved in the recycling of Sec [4]. However,
the means by which SPS1 may be involved in Sec recy-
cling has not been determined. Recently, it was found
that the targeted depletion of SPS1 by RNA interference
in Drosophila SL2 cells causes growth inhibition, ROS
induction and megamitochondrial formation by increas-
ing intracellular glutamine levels [17]. Interestingly,
human SPS1 was found to interact with the soluble liver
antigen, which was recently identified as eukaryotic Sec
synthase (SecS), and the binding reaction was enhanced
by Sec tRNA methylase designated SECp43 [18,19]. It
should be noted that SecS is a pyridoxal phosphate
(PLP)-dependent enzyme and, therefore, the uptake
and/or activation of vitamin B6 may be related to sele-
nium metabolism [20,21].
Vitamin B6 is a water-soluble compound that contains
a pyridine ring. Vitamin B6 is present in nature as sev-
eral different forms such as pyridoxal (PL), pyridoxine
(PN), pyridoxamine (PM) and their 5’-phosphorylated
forms [22]. Before use, these vitamers are converted to
PLP, which is the metabolically active form. PLP is used
as a cofactor for PLP-dependent enzymes, where the
pyridine ring acts as an electron sink during enzymatic
reactions. Since animals, including humans, cannot
synthesize vitamin B6, they must obtain it from their
diet [23]. PLP can be synthesized through several differ-
ent pathways, and two types of enzymes, kinases and
oxidases, participate in these pathways. For PM to be
converted to PLP, it is first phosphorylated by a kinase
(PL/PM/PN kinase) to form pyridoxamine phosphate
(PMP), and then the PMP is oxidized to form PLP using
an oxidase (PMP/PNP oxidase). PN can also be con-
verted to PLP using the same kinase and oxidase used
for PM. In this case, the phosphorylated intermediate is
pyridoxine phosphate (PNP). However, PL can be
directly converted to PLP by phosphorylation using a
kinase [24]. Therefore, kinases and oxidases are impor-
tant enzymes for PLP synthesis.
There are more than 100 PLP-dependent enzymes in a
cell that perform essential roles in various metabolic
pathways including amino acid metabolism (such as
amino acid synthesis and degradation), fatty acid metabo-
lism (such as the synthesis of polyunsaturated fatty acids),
and carbohydrate metabolism (such as the breakdown of
glycogen) [[23] and references therein]. The PLP-depen-
dent enzymes that participate in amino acid metabolism
can be classified into 4 categories: transaminase, race-
mase, decarboxylase and a,b-eliminase [25]. Interestingly,
the biosynthesis of Sec can be mediated by cystathionine
b-synthase (CBS) using serine as a precursor and it can
also be synthesized by cystathionine g-lyase (CGL) from
selenocystathionine [26,27]. Both CBS and CGL are PLP-
dependent enzymes [28]. In addition, enzymes that are
involved in the degradation of Sec, such as selenocysteine
lyase (SCL), D-selenocystine a,a n db-lyase, use PLP as a
cofactor [29]. Recently, it was found that SCL can inter-
act with SPS1 [30]. Therefore, it seems that vitamin B6
participates in the metabolism of Sec, i.e., in the bio-
synthesis and/or decomposition of Sec.
In the present study, we found that the knockdown of
SPS1 led to the down regulation of genes involved in
PLP biosynthesis, which, in turn, induced the formation
of megamitochondria and the expression of genes
responsible for innate immunity. Our findings suggest
that SPS1 primarily regulates PLP biosynthesis, and the
intracellular PLP level affects various biological pro-
cesses such as amino acid metabolism, megamitochon-
drial formation and innate immune response.
Results
Identification and temporal clustering of differentially
expressed genes
After the addition of double stranded RNAs targeting
SPS1 to the culture medium, total RNAs were isolated
on days 1, 3 and 5 after treatment and subjected to
microarray analysis using Affymetrix microchips (GEO
accession number: GSE 17685). Because megamitochon-
drial formation begins 3 days after knockdown [17],
transcriptomes were analyzed before and after megami-
tochondrial formation to find the primary target of
SPS1. The knockdown efficiency was approximately 90%
which was similar with that obtained in the previous
work [17]. The log2 values of signal intensity of 18,952
transcripts on each chip were obtained after normaliza-
tion. By performing two-way ANOVA analysis (adjusted
P-value < 0.1) against the log2 values of signal intensities
of transcripts, a total of 238 genes were found to be dif-
ferent in their expression between knockdown and con-
trol cells. Twenty-three genes were selected by model 1
and 227 genes by model 2, with 12 genes being com-
mon between the two models (Figure 1A; Additional
File 1 shows the list of DEGs).
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Figure 1 Identification and clustering of DEGs. A. DEGs expression profiles ordered by fold changes on day 5 in each model. The number in
bracket represents the gene numbers including each model. Genes selected by both model (model 1 and 2) overlapped between model 1 and
model 2. B. DEGs were classified into six clusters according to their temporal expression patterns using SOM clustering methods. The number in
each panel represents the number of genes in each cluster. Normalized intensities are log2-values of signal intensity. C. The range of expression
ratios of DEGs in each cluster was drawn with a box plot. The line in each box designates the median quartile (Q2). Dashed lines designate the
threshold values (log2 ratio of +0.75 and -0.75) for determining clusters of genes whose expressions were changed significantly. The dotted
boxes represent the clusters showing their inter-quartile ranges (IQRs) and are the outliers of the threshold, and the genes in those clusters were
selected as gene sets for GO analysis.
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by SPS1 knockdown, clustering of DEGs was performed
according to their temporal expression using by self-
organizing map (SOM) algorithms [31]. As a result, the
DEGs were classified into 6 clusters (Figure 1B). Genes
belonging to cluster 1 (33 genes) showed continuous
increase in their expression by SPS1 knockdown, and
most of them showed more than 4-fold increase on day
5. The expression patterns of genes in cluster 2 (77
genes) were similar to those of cluster 1, but the average
expression level was lower than that of cluster 1. Genes
in cluster 3 (9 genes) showed down-up patterns of
expression. The expression of cluster 4 genes (12 genes)
was decreased until day 3, and the expression level was
maintained afterward. The expression pattern of genes
in cluster 5 (27 genes) was a down-down type. Genes in
cluster 6 (80 genes) showed an expression pattern simi-
lar to that of cluster 5 genes. However, the average level
of expression of cluster 5 genes was much lower than
that of cluster 6 genes.
Using six clusters resulted from above, the expression
ratios of DEGs composing a cluster were drawn as a box
plot according to their sampling date (days 1, 3, and 5).
As shown in Figure 1C, the median values (Q2s) of all
clusters were close to zero on day 1. However, Q2s of
clusters 3, 4 and 5 on day 3 were significantly decreased.
On day 5, Q2s of clusters 1 and 2 were significantly
increased, while those of clusters 4, 5 and 6 decreased.
The interquartile ranges (IQRs) of each cluster were
compared to select cluster(s) whose IQRs were signifi-
cantly deviated. Clusters 3, 4 and 5 revealed significant
down regulation compared to the other clusters on day 3.
The IQRs of those clusters on day 3 were lower than
-0.75. Therefore, the threshold to select clusters whose
expression was significantly changed at a specific sam-
pling date was set to the absolute value of 0.75 (see the
dashed lines in Figure 1C). A gene pool composing the
selected clusters that showed the same expression pattern
at the same sampling date was used as a gene-set for gene
ontology analysis. As shown in Figure 1C, there is no
cluster showing that their IQRs were located at the out-
side of the threshold range (-0.75~ +0.75) on day 1; thus,
no gene was selected for GO analysis from day 1 samples.
However, on day 3, the IQRs of clusters 3, 4 and 5 were
lower than the lower threshold (-0.75), and the genes in
these clusters were defined as the early/down gene-set
because their expressions were decreased. Clusters 1 and
2 showed a significant increase in their expression on day
5, and the genes in those clusters were defined as the
late/up gene-set. On the other hand, genes in clusters 4,
5 and 6 showed significant down-regulation in their
expression, and they were defined as the late/down gene-
set (the dotted boxes in Figure 1C; Additional File 2 for
the list of genes in these gene-sets).
Identification of statistically overrepresented biological
processes by gene ontology analysis
To predict overrepresented metabolic pathway or biolo-
gical process that is significantly affected by SPS1 knock-
down, gene ontology (GO) analysis [32] was performed
with 3 gene-sets (early/down, late/up and late/down)
previously defined using BinGO software [33]. The para-
meters for statistical test and multiple testing correction
were used to binomical test and Bonferroni family-wise
error rate (FWER) correction [34], respectively. As a
result, total 29 GO biological process terms and 23
genes, which are included in each GO term, were
selected. (Table 1; see also Additional File 3). The terms
related to vitamin B6 biosynthesis were selected as sig-
nificant GO terms from the early/down gene-set (p-
value = 2.48 e-02). Changing the parameters for statisti-
cal tests and multiple testing corrections to Benjamini-
Hochberg false discovery rate (FDR) [34] and hypergeo-
metric test did not change the results (Additional File
4), suggesting vitamin B6 biosynthesis is the only signifi-
cant biological process affected by SPS1 knockdown at
the early stage. GO terms selected from the late/up
gene-set could be categorized into two distinct biologi-
cal processes: defense (immune) response and carboxylic
acid (amino acid) metabolism (Table 1). Both defense
response (p = 6.22 e-08) and carboxylic acid processes
(p = 8.17 e-05) were selected with significantly high
probabilities. Interestingly, 15 genes among 21 genes
( 7 2 % )s e l e c t e df r o mt h el a t e / u pg e n e - s e ta r ek n o w nt o
participate in defense response. In addition, 7 of 15
defense response genes encode antimicrobial peptide
(AMP). No GO term was selected from the late/down
gene-set. These results strongly suggest that SPS1 affects
vitamin B6 biosynthesis at the early stage and then
defense response and amino acid metabolism through
vitamin B6 activity.
Validation of expression by quantitative PCR
Since the cells that were not transfected with double
stranded RNA (dsRNA) as control for microarray ana-
lysis, it was necessary to confirm that the selected
DEGs have the same expression pattern with the cells
transfected with control dsRNA. We used GFP dsRNA
as a control RNA and quantitative PCR (qPCR) was
carried out to measure the expression levels. Of 23
DEGs from the selected GO terms (genes in Table 1),
15 genes were arbitrarily chosen, and their expressions
were compared between SPS1 knockdown and GFP
dsRNA treated control cells. As shown in Figure 2, all
tested genes showed the same pattern of expression as
that obtained from microarrays. It should be addressed
that all the genes involved in vitamin B6 synthesis and
encoding AMP were tested and showed the same
expression patterns.
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Page 4 of 12Table 1 List of biological processes selected from gene ontology analysis
Gene-set Represented biological
process
Max. corrected p-
value
Selected genes
Early/
down
Vitamin B6 biosynthesis 2.48 e-02 CG11899, CG31472
Late/up Defense response 6.22 e-08 AttB, AttD, CecB, DptB, Dro, Drs, Mtk, egr, pirk, PGRP-LF, PGRP-SD, W, Cyp6a8,
Cyp12a4, Toll-7
Carboxylic acid metabolism
(Amino acid metabolism)
8.17 e-05 arg, CG8745, Gs1, Oat, Pepck, yellow-f
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Figure 2 Validation of the selected genes by quantitative PCR. Five days after adding dsRNA, the mRNA levels of selected genes were
measured by real time RT-PCR using rp49 for normalization. The y axis represents the relative mRNA level of each gene in the cells treated SPS1
dsRNA (SPS1i) to that treated GFP dsRNA (GFPi). The mRNA level of GFPi was set to 100%. The gene symbol is marked above each graph.
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Page 5 of 12Intracellular pyridoxal phosphate level was decreased by
SPS1 knockdown
Because GO analysis predicted that vitamin B6 biosynth-
esis was the only pathway affected at early stage by SPS1
knockdown and the expression patterns of genes involved
in vitamin B6 synthesis were confirmed, it can be specu-
lated that levels of PLP will decrease by SPS1 knockdown.
To test this hypothesis, intracellular PLP levels were mea-
sured after SPS1 knockdown. As shown in Figure 3A,
PLP levels in the cells where SPS1 was knocked down
decreased by approximately twofold compared to the
control cells. The PLP concentration in SPS1 knockdown
cells was 37.23 ± 0.66 pmol/mg protein. On the other
hand, the PLP levels in the non-treated control and in
GFP dsRNA treated cells (negative control cells) were
73.59 ± 1.31 and 75.37 ± 0.89 pmol/mg protein, respec-
tively. PLP levels in SPS1 knockdown cells were similar
to those observed in 4-deoxypyridoxine (4-DPN), which
is an inhibitor of PLP biosynthesis, treated cells (positive
control cells). These results indicate that the function of
SPS1 is to regulate the biosynthesis of PLP in the cells.
Inhibition of PLP biosynthesis and SPS1 knockdown
showed similar expression patterns
Because intracellular PLP levels were significantly reduced
after SPS1 knockdown, it can be assumed that PLP bio-
synthesis is the primary target of SPS1, and the inhibition
of PLP synthesis by treating cells with inhibitors will cause
similar gene expression patterns as those resulting from
SPS1 knockdown. To test this hypothesis, Drosophila cells
were treated with 4-DPN for 5 days, and the expression
level of genes selected by GO analysis was measured with
RT-PCR. As shown in Figure 3B, the level of expression of
the early/down genes (CG31472 and CG11899)w a sn o t
changed by 4-DPN treatment. Because 4-DPN inhibits
only the function of proteins that participate in PLP synth-
esis and does not affect the expression of genes encoding
those proteins, it is reasonable that 4-DPN does not affect
the expression of CG31472 and CG11899.H o w e v e r ,t h e
treatment of 4-DPN affected the expression of genes com-
prising the late/up and late/down gene-sets. Of the 17
genes tested, 14 genes (82%) showed expression patterns
similar to those observed by microarray analysis. It should
be noted that the late gene-sets include genes responsible
for defense response and amino acid metabolism. These
results strongly suggest that PLP synthesis is the primary
target of SPS1 and that intracellular PLP levels regulate
other important biological processes such as defense sys-
tem and amino acid metabolism.
The reduction of intracellular PLP level inhibits cell
growth and induces megamitochondrial formation
In our previous study, we discovered that SPS1 knock-
down leads to cell growth inhibition and induction of
Figure 3 SPS1 knockdown causes a decrease in intracellular
PLP levels. A. Five days after SPS1 dsRNA or 4-DPN was added to
the medium, intracellular PLP levels were measured as described in
Methods. dsRNAs and 4-DPN used are shown on the x-axis.
Experiments were performed in triplicate and error bars denote the
standard deviation from the mean of three independent
experiments. Statistical significance was tested by one-way ANOVA
followed by Tukey’s multiple comparison test. ** indicates
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Page 6 of 12megamitochondrial formation [17]. As shown in Figure
4A, cell growth was significantly inhibited after the cells
were treated with 4-DPN suggesting that the cell growth
retardation induced by SPS1 knockdown was due to
vitamin B6 starvation. Another prominent phenotypic
change induced by SPS1 knockdown is megamitochon-
drial formation. Drosophila SL2 cells were treated with
4-DPN for 3 days and examined under a confocal
microscope after the mitochondria were stained with
JC-1. As shown in Figure 4B, the cells treated with 4-
DPN formed megamitochondria that were similar to
those observed in the SPS1 knockdown cells in terms of
their size and number. Interestingly, the number of
polar mitochondria (red dots in Figure 4B) in 4-DPN
treated cells was similar to that in the control cells, and
this mitochondrial polarity pattern was also similar to
that observed in the SPS1 knockdown cells. Since mega-
mitochondria formation can arise from several different
pathways, we examined whether megamitochondrial for-
mation occurred by the activation of Gs1 and l(2)01810.
A ss h o w ni nF i g u r e4 C ,b o t ht h el e v e lo fGs1 and l(2)
01810 expression was increased. These results strongly
suggest that the formation of megamitochondria, which
is the most prominent phenotype from SPS1 knock-
down, is induced by the lack of intracellular PLP.
Discussion
We assumed that the genes whose expression was chan-
ged at the early stage after knockdown are involved in the
primary target process regulated by SPS1. To identify the
primary target, DEGs were isolated after microarray analy-
sis and classified according to their temporal expression
pattern; GO terms of early changed DEGs were analyzed
using BinGO software. It is interesting that only PLP bio-
synthesis was predicted from the early/down gene set,
even though the parameters were changed. As shown in
Table 1, the DEGs in the early/down gene set that are
involved in vitamin B6 synthesis are CG31472 and
CG11899. CG31472 is an ortholog of mammalian pyridox-
ine phosphate oxidase (PNPO), which catalyzes PLP pro-
duction from PMP and PNP and PL production from PN
or PM by oxidizing the substrates [35]. The function of
CG11899 was not determined experimentally. However, it
Figure 4 The effect of PLP synthesis inhibition on cell growth
and megamitochondrial formation. A. SL2 cells were seeded in a
96- well plate (2.5 × 10
4 cells/well) and the growth rate was
examined by the MTT assay in 4-DPN-treated cells as described [17].
Control cells were not treated with 4-DPN. Experiments were
performed in triplicate, and error bars denote the standard
deviation from the mean of three independent experiments. B.
Three days after 4-DPN treatment, cells were stained with JC-1 and
significance at p < 0.01. B. Five days after treatment of cells with
dsRNAs and 4-DPN, expression patterns of genes selected by GO
analysis were measured by RT-PCR as described in Methods. Tested
genes and GO terms of the gene are shown on the left of each
panel. VB, vitamin B6 biosynthesis; DR, defense response; AA, amino
acid metabolism; Con, internal control. The effect of 4-DPN on gene
expression is represented as the PLP effect. The + and - symbol
designate consistency and inconsistency of expression pattern of
each gene between SPS1 knockdown and 4-DPN treated cells,
respectively. rp49 was used as an internal control.
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notransferase and PdxC of E. coli, which are responsible
for producing 4-phospho-hydroxy threonine, a precursor
of the pyridoxine ring [36]. Therefore, it seems that
CG11899 plays a role in producing precursors of vitamin
B6. Interestingly, intracellular PLP levels were decreased
even though only two genes among four genes that are
involved in the PLP biosynthesis pathway in Drosophila
cell were down-regulated (see Additional File 5). This
result suggests that these two genes are involved in an
essential step of PLP biosynthesis, or SPS1 may also regu-
late the other proteins involved in PLP biosynthesis post-
transcriptionally.
Because PLP is used as a cofactor for various enzymes
that are important for many metabolic pathways, includ-
ing amino acid metabolism, the inhibition of PLP bio-
synthesis will lead to the inhibition of cell growth. The
inhibition of cell growth induced by SPS1 knockdown
seems to be mediated by a decrease in intracellular PLP
levels. Specific inhibition of PLP synthesis by 4-DPN
treatment led to growth inhibition (Figure 4A), suggest-
ing the growth inhibition by SPS1 knockdown is caused
by down-regulation of PLP synthesis.
As described in the Results, down-regulation of genes
responsible for PLP synthesis stimulated the expression
of DEGs that participate in the defense response. In
addition, most of the late gene-sets showed the same
pattern of expression as that seen when cells were trea-
ted with 4-DPN (Figure 3B). The relationship between
vitamin B6 and cellular defense, however, has not been
demonstrated before this study. Previously, it was
reported that the knockdown of SPS1 induced diphtheri-
cin expression in Drosophila SL2 cell when a genome-
wide knockdown was performed [37]. The inhibition of
PLP synthesis also induced the expression of various
AMPs, including dipththericin. Therefore, SPS1 plays a
key role in innate immune responses, including AMP
production, by regulating PLP level in the cell. The
mechanism by which vitamin B6 regulates the innate
immune system remains to be elucidated.
The fact that the treatment of 4-DPN, like SPS1
knockdown, induced megamitochondrial formation
indicates that intracellular glutamine levels increased
with the inhibition of PLP synthesis. Because PLP is
used as a cofactor for enzymes that have transaminase
activity, it is reasonable to assume that low levels of PLP
will lead to the inhibition of synthesis of amino acids
such as glutamate or glutamine. However, the inhibition
of PLP biosynthesis induced the expression of Gs1 and l
(2)01810 (Figure 4C). These two genes are involved in
the increase of intracellular glutamine levels [17]. These
results suggest that the lack of PLP in the cell provides
a signal for compensatory induction of some genes
responsible for amino acid metabolism. PLP regulation
of the expression of Gs1 and l(2)01810 has not been
elucidated.
A model for the molecular pathways regulated by
SPS1 is summarized in Figure 5. SPS1 regulates the
intracellular level of PLP by regulating the expression of
genes responsible for PLP biosynthesis. Optimal levels
of PLP do not induce defense response signaling and
glutamine synthesis. However, low levels of PLP induce
both defense signaling and glutamine synthesis. Once
defense signaling is stimulated, genes responsible for the
innate immune system, including AMPs, are activated.
The activation of genes responsible for glutamine
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amino acid metabolism
PLP
defense response
ATTB
ATTD
CECB
DRS
DPTB
DRO
MTK
antimicrobial  
peptides
immune signaling 
proteins
PGRP-LF
PGRP-SD
TOLL-7
TAMO
glutamate
glutamine
megamitochondrial 
formation
ದ 10                              10 fold
cell growth
L(2)01810
CG11899
Figure 5 A hypothetical model for molecular pathways
regulated by SPS1. A detailed explanation is provided in the
Discussion. Molecular or cellular processes are marked with boxes.
Proteins and molecules are in boldface letters. The expression levels
of genes are marked with colors. The arrow and blocked line (┤)
represent positive and negative regulation, respectively. The dashed
line indicates that the effect was not proved experimentally.
then observed under a confocal microscope as described in
Methods. Control cells were grown in the absence of 4-DPN. Scale
bars represent 5 μm. C. Five days after treatment of cells with
dsRNAs and 4-DPN, mRNA levels of GS1 and l(2)01810 were
measured by realtime RT-PCR as described in Materials and
Methods. dsRNAs and 4-DPN treated are shown on the X axis.
Experiments were performed in triplicate, and error bars denote the
standard deviation from the mean of three independent
experiments. Statistical significance was tested by one-way ANOVA
followed by Tukey’s multiple comparison test. *** indicates
significance at p < 0.001.
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Page 8 of 12synthesis leads to megamitochondrial formation. The low
level of intracellular PLP also leads to growth inhibition,
presumably through induction of megamitochondrial for-
mation and/or other biological processes. This hypothesis
is supported by the observation of cell growth inhibition
after the treatment of cells with 4-DPN (Figure 4A).
However, it is not clear whether the growth inhibition is
caused by the induction of both glutamine and AMP
synthesis or one of these. In our previous study, it was
found that conditions inducing megamitochondrial for-
mation, such as the over expression of GS1 and l(2)
01810, also resulted in cell growth inhibition [17]. But
there is no report showing that the condition for the
induction of defense system inhibits cell growth. There-
fore, the inhibition of cell growth by AMP induction is
represented as a dotted line in Figure 5.
Although SPS1 was found to regulate the biosynthesis
of vitamin B6, the mechanism or signal pathway to
which SPS1 is related has not been determined. Because
SPS1 is localized to both plasma and nuclear mem-
branes [38], it can be speculated that SPS1 regulates sig-
nal transduction by transducing signals on the plasma
membrane or by transporting messengers or transcrip-
tion factors through the nuclear membrane. The treat-
ment of cell with 4-DPN or SPS1 knockdown induced
the expression of PGRP-SD and Toll-7, which are
involved in the Toll signaling pathway, and PGRP-LF,
which is an activator of the IMD pathway (Figure 5). In
addition, Tamo, which is a negative regulator for nuclear
import of Dorsal, was found to be one of the down-
regulated DEGs. These results strongly suggest that
PLP, which is regulated by SPS1, participates in both
the Toll and the IMD pathways.
Interestingly, SPS1 knockdown induced down-regula-
tion of CG1753, which encodes cystathionine b-synthase
(see Table 1). Cystathionine b-synthase catalyzes both
L-cystathionine and L-selenocysteine synthesis [28].
Therefore, it seems that SPS1 regulates the synthesis of
Sec indirectly by regulating the expression of Sec
synthesizing enzymes.
Conclusions
In this study, we predicted that vitamin B6 biosynthesis
is the primary target of SPS1 by employing bioinfor-
matics methods such as microarray and GO analyses
and confirmed the prediction experimentally by showing
that PLP levels were decreased by SPS1 knockdown and
that the inhibition of PLP biosynthesis caused the same
phenotypes as SPS1 knockdown.
Methods
Materials
Materials were purchased from the following sources:
Drosophila Schneider cell line 2 (SL2) was purchased
from Invitrogen, HyQ SFX-Insect medium from
Hyclone, T3 Megascript kit from Ambion, RNeasy mini
kit from Qiagen, GeneChip Drosophila genome 2.0 array
from Affymetrix, SYBR Green mix from Applied Biosys-
tems, TRIzol reagent from Invitrogen, Moloney murine
leukemia virus reverse transcriptase from Super-Bio, 4-
deoxypyridoxine hydrochloride from TCI, 5’,6,6’-tetra-
chloro-1,1’,3,3’-tetraethylbenzimidazolyl-carbocyanine
iodide (JC-1) from Molecular Probes, and oligonucleo-
tides from Cosmo Genetech. The sequences of oligos
used for RT-PCR are listed in Additional File 6.
SL2 cell culture and RNA interference
SL2 cell culture and preparation of double-stranded
RNAs were carried out as described [17]. Briefly, for
RNA interference, 0.25 × 10
6 cells were plated on a 24-
well plate containing 0.5 ml of HyQ SFX-Insect med-
ium. Four micrograms of dsRNAs were added directly
to the medium and incubated for 48 hr and cells were
split into appropriate culture dishes for further incuba-
tion and other experiments.
Microarray experiment
Microarray experiments were performed using the Gen-
eChip Drosophila genome 2.0 array. After the addition
of double stranded RNAs targeting SPS1 to the culture
medium, total RNA was extracted from SL2 cells treated
with or without SPS1 dsRNA on day 1, 3 and 5 after
treatment using the RNeasy mini kit according to the
manufacturer’s instructions. The cells that were not
treated with any dsRNA were used as controls. The
RNA quality was checked using Experion (Applied Bio-
systems) according to the manufacturer’s instructions.
Five micrograms of total RNAs were reverse transcribed
with oligo-dT primer containing a T7 RNA polymerase
promoter (TAATACGACTCACTATAGGG). Biotin-
labeled cRNAs were generated from the cDNA sample
by in vitro transcription with T7 RNA polymerase. The
labeled cRNAs were fragmented to an average size of
35-200 bases by mild alkaline treatment at 94°C for 40
min. Fragmented cRNAs were hybridized with probes
that are on GeneChip Drosophila genome 2.0 array, and
the chips were washed and stained in the Affymetrix
Fluidics Station 450 by following the procedures estab-
lished by Affymetrix (Affymetrix GeneChip R Expression
Analysis Technical Manual). The signals were scanned
using the GeneChip Scanner 3000 7G (Affymetrix).
Analysis of microarray data
The raw data were imported into Acuity 4.0 software
(Molecular Devices, Inc.), and a background adjustment
and normalization were performed using robust multi-
chip average (RMA) and quantile methods, respectively,
implemented in Acuity 4.0 software [39,40]. To identify
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Page 9 of 12differentially expressed genes (DEGs), a two-way analysis
of variance (ANOVA) model was used and fitted using
the R software http://www.r-project.org, as described by
Park et al [41]. Two models were considered to identify
D E G s .M o d e l1c o n t a i n sg r o u pa n dt i m ee f f e c t sa sw e l l
as their interactions. Model 1 allows the expression level
of genes to change over time (days 1, 3 and 5) and these
change patterns to differ between groups (control and
knockdown). Model 2 includes only group and time
effects assuming that the expression level of genes
changes over time but these change patterns are the
same between groups. From Model 1, DEGs were iden-
tified by the genes with significant interaction effects,
while from Model 2 DEGs were identified by the genes
with significant group effects. The p-values were
adjusted by Westfall and Young’s method [42]. The
genes with adjusted p-values less than 0.1 were
identified.
To classify DEGs according to their temporal expres-
sion pattern, DEGs were clustered using a self-organiz-
ing map (SOM) algorithm implemented in Acuity 4.0
[31]. The ratios of normalized log2 values of DEGs
between SPS1 knockdown cells and control cells were
used as input data and the SOM map size was set to 3
× 2. The ranges of expression ratios of DEGs within
each cluster at each sampling date were displayed by
box plot using R software. The interquartile ranges
(IQRs) of each cluster were compared to select cluster
(s) whose IQRs were significantly deviated. The criterion
for determining clusters within which gene expressions
were changed significantly was set to 0.75, i.e., when the
interquartile range (IQR) of a cluster was larger than
+0.75 or smaller than -0.75, the cluster was selected as
significantly changed. This is because 0.75 is the thresh-
old value to isolate clusters on day 3 (see Results for
more details). The genes composing a cluster selected at
the early stage (day 3) were defined as an early respond-
ing gene-set and those composing a cluster selected at
the late stage (day 5) were defined as a late responding
gene-set.
GO analysis was performed by BiNGO version 2.3
[33], which is plugged in Cytoscape [43]. Gene symbols
of each gene-set were used as input data. The para-
meters were set as follows: assessment was set to overre-
presentation, statistical test to binomial test, multiple
testing correction to FWER correction, significance level
to 0.05. Among GO evidence codes, inferred from elec-
tronically annotated (IEA) were discarded. The most sig-
nificant pathway was predicted by considering the
selected GO terms and visualized output.
RT-PCR and quantitative real time RT-PCR
RT- PCR and real time PCR were carried out as
described [17]. Briefly, total RNA was isolated from the
cells using the TRIzol reagent. cDNAs were synthesized
from total RNAs with Moloney murine leukemia virus
reverse transcriptase and oligo (dT) primers according
to the manufacturer’s protocols. RT-PCR was performed
with 0.1 μg of template total RNA and specific primers
(Additional File 6). RT-PCR products were electrophor-
esed on a 2% agarose gel and visualized by ethidium
bromide. For the measurement of relative mRNA levels
of each gene, real time PCR was carried out using an
ABI 7300 real time PCR system (Applied Biosystems) as
follows. cDNAs were amplified using SYBR Green mix
and specific primers for 40 cycles [initial incubation at
50°C for 2 min and then at 95°C for 10 min, and 40
cycles (95°C for 15 sec, 55°C for 1 min and 72°C for 1
min)]. Output data were obtained as Ct values using
Sequence Detection Software (SDS) version 1.3 (7300
System, Applied Biosystems) and the differential mRNA
expression of each gene between control and knock-
down cell was calculated using the comparative Ct
method [44]. RP49 mRNA, an internal control, was
amplified along with the target genes, and the Ct value
of RP49 used to normalize the expression of target
genes.
Measurement of intracellular PLP concentration
Cellular PLP levels were determined using the method
previously described [45] with minor modifications. At
day 5 after treatment with dsRNA or 4-DPN, cells were
washed with phosphate buffered saline and harvested.
Cells (6 × 10
7) were lysed by resuspension in 600 μlo f
distilled water. Cell extracts were induced to produce
the semicarbazon derivative of PLP as follows: 40 μlo f
250 mg/ml of both semicarbazide and glycine were
added into 500 μl of cell extracts or PLP standard. The
mixture was vortexed and incubated at room tempera-
ture in the dark for 30 min. Proteins were then precipi-
tated by adding 50 μlo f6 0 %H C l O 4 into the mixture,
and the solution was thoroughly mixed for 1 min. The
solution was clarified by centrifugation for 10 min at
15,000 × g, and 30-50 μl of a 25% NaOH solution was
added to the supernatant to achieve a pH between 3.0
and 5.0. HPLC was performed using a ZORBAX SB-C18
column (4.6 mm × 25 cm, PN 880975902) and an iso-
cratic mobile phase consisting of 60 mM sodium phos-
phate (pH 6.5), 400 mg/l EDTA and 9.5% methanol at a
flow-rate of 1 ml/min, and the derivatized PLP was
quantified using a Waters™ 474 scanning fluorescence
detector by setting excitation and emission wavelengths
to 380 and 450 nm, respectively.
Mitochondrial staining and confocal microscopy
Mitochondrial staining and confocal microscopy were
carried out as described [17]. Briefly, SL2 cells (0.5 ×
10
6) were plated onto a chambered coverglass one day
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Page 10 of 12before staining. Cells were incubated with 1 μg/ml JC-1
for 30 min at 25°C, washed three times with HyQ-SFX-
Insect medium and observed with a LSM510 confocal
microscope (Carl Zeiss) at 512 × 512 pixel resolution
through an X63 C-Apochromat objective. Excitation
wavelengths for JC-1 aggregate and JC-1 monomer were
543 and 488 nm, respectively.
Additional material
Additional file 1: List of differentially expressed genes (DEGs). The
list of DEGs whose expressions were changed more than 2 fold at least
at one time point.
Additional file 2: Six Clusters of DEGs and gene-sets used for gene
ontology analysis. DEGs were grouped into six clusters and each cluster
was classified as one of 3 gene-sets, after box-plotting the DEGs in each
cluster. All the DEGs in each gene-set were used for gene ontology
analysis.
Additional file 3: List of biological process terms selected by GO
analysis with three gene-sets. This table is an output obtained by
running BinGO software showing genes and their GO biological process
terms. The parameters used are described above the table.
Additional file 4: Hierarchical structures of GO terms obtained by
performing early/down gene-set with different parameters. Panels A
and B were examples of hierarchical structures of GO terms obtained by
analyzing early/down gene set with BinGO software. They showed similar
results, although different parameters were used.
Additional file 5: Schematic diagram of vitamin B6 metabolic
pathway. The original vitamin B6 metabolic pathway diagram (collected
from KEGG database) was modified by indicating DEGs and by showing
their expression levels, after SPS1 was knocked down.
Additional file 6: Oligonucleotide sequences used as primers for RT-
PCR or real-time PCR. List of all oligonucleotides used for RT-PCR and
real-time PCR.
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